Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.260
+0.020 (1.61%)
At close: May 13, 2025, 4:00 PM
1.250
-0.010 (-0.79%)
Pre-market: May 14, 2025, 8:16 AM EDT
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc).
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Adi George |
Contact Details
Address: Building 7, Kiryat Atidim Tel Aviv, 6158002 Israel | |
| Phone | 972 77 331 0156 |
| Website | chemomab.com |
Stock Details
| Ticker Symbol | CMMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534248 |
| CUSIP Number | 03280X102 |
| ISIN Number | US16385C1045 |
| Employer ID | 81-3676773 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer and Vice President of Drug Development |
| Barbara Lindheim | Consulting Vice President of Investor and Public Relations, Strategic Communications |
| Dr. David M. Weiner M.D. | Interim Chief Medical Officer |
| Jack Lawler | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | SCHEDULE 13G/A | Filing |
| Apr 4, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | 6-K | Report of foreign issuer |
| Dec 10, 2024 | EFFECT | Notice of Effectiveness |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |